ANI Pharmaceuticals, Inc. $ANIP Shares Bought by Bridge City Capital LLC

Key Points

• Bridge City Capital increased its ANI Pharmaceuticals stake by 56.7% in the third quarter to 52,705 shares valued at approximately $3.83 million. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS and $266.04 million in revenue, with revenue up 25.8% year over year. The company issued fiscal 2026 EPS guidance of $9.19–$9.69.
• Analyst sentiment is mixed, with three Buy and four Hold ratings and a consensus price target of $99.60 versus the stock’s recent $72 price. Insiders have sold 30,412 shares worth about $2.22 million over the past 90 days.

Bridge City Capital LLC lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 56.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,705 shares of the specialty pharmaceutical company's stock after acquiring an additional 19,080 shares during the period. Bridge City Capital LLC owned 0.23% of ANI Pharmaceuticals worth $3,829,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Bank of America Corp DE bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $15,154,000. NFJ Investment Group LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $2,766,000. Walleye Capital LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $8,784,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in ANI Pharmaceuticals in the 2nd quarter worth approximately $1,449,000. Finally, Jupiter Topco LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at $6,597,000. Institutional investors and hedge funds own 76.05% of the company's stock.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company's stock, valued at $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Stephen Carey sold 2,850 shares of the business's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total transaction of $207,679.50. Following the transaction, the chief financial officer owned 166,143 shares in the company, valued at approximately $12,106,840.41. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 30,412 shares of company stock valued at $2,220,970. 8.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective for the company. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Finally, Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $99.60.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $72.00 on Monday. The company's 50 day simple moving average is $72.96 and its 200 day simple moving average is $77.68. The firm has a market capitalization of $1.65 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 2.32 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a fifty-two week low of $69.58 and a fifty-two week high of $95.57. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. ANI Pharmaceuticals's revenue for the quarter was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.